The main purpose of this study is to demonstrate that LML134 can increase wakefulness compared to placebo in patients with shift work disorder (SWD) measured by objective and subjective endpoints of wakefulness, i.e. the sleep latency in the multiple sleep latency test (MSLT) and the Karolinska Sleepiness Scale (KSS), respectively. Safety and PK of LML134 will also be evaluated. In addition, novel methodologies to measure wakefulness and sleep will also be tested and compared to gold standard methods like the MSLT and polysomnography (PSG). The aim of such comparisons is to evaluate the usefulness of the new technologies in clinical studies and provide preliminary validation data.